Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • FDA’s leadership void leaves biotech with renewed ‘uncertainty’
  • Policy / Pricing

FDA’s leadership void leaves biotech with renewed ‘uncertainty’

BioPharma Dive

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

Read full story

pharminent May 13, 2026 (Last updated: May 16, 2026)

BioPharma Dive

Marty Makary’s resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
Next: Joint MHRA/NICE pathway ‘benefits industry over patients’

Related Stories

  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.